The subscription of new shares has long been known, and there will be a new pharmaceutical stock next week!

[Pharmaceutical Network Pharmaceutical Stock Market] Next week (July 11 to July 15), there will be 7 new A-share subscriptions, namely Longda Shares, Guobo Electronics, Lixin Energy, Chuhuan Technology, Jintuo Shares, Yixing Fang Bio and Xixi Testing, of which Longda, Guobo Electronics and Yifang Bio are only on the Science and Technology Innovation Boa.
From the perspective of the Shenwan industry, 7 new stocks are concentrated in the fields of automobile, pharmaceutical biology, social services, environmental protection, public utilities, e.
Among them, Yifang Biology is a new pharmaceutical sto.
Yifang Bio will be subscribed on July 14, and a total of 115 million shares will be issued, of which 11 million shares will be issued online, and the subscription limit will be 16,000 shar.
According to the data, Yifang Bio is an innovative drug research and development company based in China with a global vision, focusing on major diseases such as tumors and metabolic diseas.
The main products include inhibitor BPI-D0316, selective estrogen receptor degrader (SERD) D-0502, urate transporter 1 (URAT1) inhibitor D-0120, KRAS G12C inhibitor D-155From the perspective of product pipeline, Yifang Bio has 1 product in the New Drug Application (NDA) stage, 3 products in the clinical trial stage and 5 preclinical research projec.
The clinical development product projects span from phase I to new drugs The research and development progress of the 4 core products is in the forefront of the world or China in multiple stages such as the listing application (ND.
Because the product has not yet been listed for sale, the company is currently in a state of lo.
Financial data shows that in 2021, the company will achieve a net profit of -358 million, a year-on-year increase of 60However, Yifang Bio focuses on research and developme.
As of the end of 2021, the company has a total of 140 research and development personnel, accounting for 932%, of which 68 have master's and doctoral degre.
Its core research and development team has an average of more than 20 years of experience in multinational pharmaceutical compani.
Rich experience, professional fields cover all aspects of new drug research and development, including disease mechanism research, target identification and confirmation, compound screening and structure optimization, API and preparation process development, clinical research and registration, which may be conducive to continuous and efficient promotion of issuance Human drug development proce.
Yifang Bio's IPO on the Science and Technology Innovation Board plans to raise a total of about 4 billion yuan, and the raised amount will be used for new drug research and development projects and headquarters base construction projec.
Among them, the new drug research and development project in the fundraising project aims to invest in the research and development of a number of clinical and preclinical products, and provide patients with safe, effective and affordable high-quality drugs through innovative research and development to meet the urgent treatment nee.
Further improve the core competitiveness of enterpris.
It is reported that the new drug R&D projects proposed by the company this time include three clinical trial products independently developed by the company and being jointly conducted by China and the United States, namely oral selective estrogen receptor degrader (SERD), URAT1 inhibitor and KRAS G12C inhibit.
Among them, SERD is an oral selective estrogen receptor degrader (SERD) independently developed by Yifang Bio for the treatment of estrogen receptor (ER) positive and human epidermal growth factor receptor (HER2) negative breast canc.

The product has shown excellent antitumor activity and safety in preclinical research and clinical trials; URAT1 inhibitor is Yifang Bio's targeted drug for the treatment of hyperuricemia and gout; KRAS G12C is used for the treatment of non-small cell lung cancer Small molecule targeted drugs for cell lung cancer, colorectal cancer and other cancers have shown excellent selectivity and tumor inhibitory effects in preclinical studi.

Research data shows that the three new drugs in the fundraising projects have broad market space and high product drugabili.
This landing on the Science and Technology Innovation Board may help Yifang Bio to accelerate the development of its existing product pipeli.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.